Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Brimonidine tartrate 2 mg/mL; ; Timolol maleate 6.8 mg/mL equivalent to timolol base 5 mg/mL;
AbbVie Limited
Brimonidine tartrate 2 mg/mL
2mg/mL, 5mg/mL
Eye drops, solution
Active: Brimonidine tartrate 2 mg/mL Timolol maleate 6.8 mg/mL equivalent to timolol base 5 mg/mL Excipient: Benzalkonium chloride Dibasic sodium phosphate heptahydrate Hydrochloric acid Monobasic sodium phosphate monohydrate Purified water Sodium hydroxide
Bottle, dropper, LDPE x 5mL, 5 mL
Prescription
Prescription
Piramal Enterprises Limited
COMBIGAN® eye drops are indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension not adequately responding to monotherapy.
Package - Contents - Shelf Life: Bottle, dropper, LDPE - 5 mL - 24 months from date of manufacture stored at or below 25°C protect from light 28 days opened stored at or below 25°C
2003-10-15
COMBIGAN ® Eye Drops-CMI Version 3.0 – PIv7.0 1 COMBIGAN ® EYE DROPS (BRIMONIDINE TARTRATE 2.0 MG PER ML AND TIMOLOL (AS MALEATE) 5.0 MG PER ML) CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about COMBIGAN ® eye drops. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using COMBIGAN ® eye drops against the benefits they expect it will have for you. If you have any concerns about using this medicine, ask your doctor or pharmacist. KEEP THIS LEAFLET WITH THE MEDICINE. YOU MAY NEED TO READ IT AGAIN. WHAT COMBIGAN ® EYE DROPS ARE USED FOR COMBIGAN ® eye drops are used to lower raised pressure in the eye and to treat glaucoma. Glaucoma is a condition in which the pressure of fluid in the eye may be high. However, some people with glaucoma may have normal eye pressure. Glaucoma is usually caused by a build up of the fluid which flows through the eye. This build up occurs because the fluid drains out of your eye more slowly than it is being pumped in. Since new fluid continues to enter the eye, joining the fluid already there, the pressure continues to rise. This raised pressure may damage the back of the eye resulting in gradual loss of sight. Damage can progress so slowly that the person is not aware of this gradual loss of sight. Sometimes even normal eye pressure is associated with damage to the back of the eye. There are usually no symptoms of glaucoma. The only way of knowing that you have glaucoma is to have your eye pressure, optic nerve and visual field checked by an eye specialist or optometrist. If glaucoma is not treated it can lead to serious problems, including total blindness. In fact, untreated glaucoma is one of the most common causes of blindness. COMBIGAN ® eye drops lower the pressure in the eye by decreasing the fluid produced and helping the flow of fluid out of the eye chamber. Although COMBI Read the complete document
COMBIGAN ® brimonidine tartrate/timolol Datasheet Version 7.0-CCDS v3.1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME COMBIGAN ® brimonidine tartrate 0.2% and timolol (as maleate) 0.5% eye drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of COMBIGAN ® eye drops contains brimonidine tartrate 2.0 mg/mL and timolol (as maleate) 5.0 mg/mL For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Sterile ophthalmic solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS COMBIGAN ® eye drops are indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension not adequately responding to monotherapy. 4.2 DOSAGE AND METHOD OF ADMINISTRATION The recommended dose is one drop of COMBIGAN ® in the affected eye(s) twice daily, approximately 12 hours apart. In order to minimise systemic absorption of COMBIGAN ® eye drops, apply pressure to the tear duct immediately following administration of the drug. As with all eye drops containing benzalkonium chloride as a preservative, there is potential for incompatibility with other topical ophthalmic medications. If more than one topical ophthalmic drug is to be used, other eye drops should not be used within five to ten minutes of using COMBIGAN ® eye drops. To avoid contamination of the solution, keep container tightly closed. Do not touch dropper tip to any surface. Discard contents 4 weeks after opening the bottle. Contents are sterile if seal is intact. PAEDIATRIC USE Safety and effectiveness in paediatric patients have not been established. During post- marketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression and somnolence have been reported in neonates, infants and children receiving brimonidine either for congenital glaucoma or by accidental ingestion. See also Contraindications. COMBIGAN ® brimonidine tartrate/timolol Datasheet Version 7.0-CCDS v3.1 GERIATRIC USE No overall differences in safety and effectiveness have b Read the complete document